Clinical trials: Prostate Cancer Stage
Prostate Cancer, Recurrent Adenocarcinoma
Jump: MR Simulation For Radiation Therapy Master Protocol
This is a master protocol for a prospective Phase I-II study evaluating feasibility and efficacy of incorporating magnetic resonance imaging (MRI) simulation into the planning of radiation treatments.
- Conditions
- Prostate Cancer, Recurrent Adenocarcinoma, Liver Cancer, Head and Neck Cancer
- Trial name
- JUMP (NCT04545957)
- Testing
- MRI Simulator, Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 86 people
- Sponsor
- Brigham and Women's Hospital
Prostate Cancer.
Phase 2 Study of G-202 in Patients With Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer
Prostate cancer that has returned after local treatment usually responds to hormone blocking treatment, but most patients eventually experience disease progression.
- Trial name
- NCT01734681
- Testing
- G-202
- Where
- United States
- Sponsor
- GenSpera, Inc.
Prostate Cancer
Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Vaccines made from a patient's white blood cells may make the body build an immune response to kill cancer cells. Interleukin-12 may kill cancer cells by stopping blood flow to the tumor and by stimulating a person's…
- Trial name
- NCT00015977
- Testing
- PSA prostate cancer vaccine, recombinant interleukin-12
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Chicago
Stage II Prostate Adenocarcinoma, Stage IIB Prostate Cancer
Hypofractionated Stereotactic Body Radiation Therapy for Patients With Prostate Cancer That Was Removed by Surgery
This phase I trial studies the side effects and the best dose of hypofractionated stereotactic body radiation therapy (SBRT) in treating patients with prostate cancer that was removed by surgery.
- Conditions
- Stage II Prostate Adenocarcinoma, Stage IIB Prostate Cancer, Stage III Prostate Adenocarcinoma
- Trial name
- NCT02446366
- Testing
- Laboratory Biomarker Analysis, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Southern California
Prostate Cancer, Sexual Dysfunction
Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy
RATIONALE: Tadalafil may help prevent erectile dysfunction (ED) in patients with prostate cancer that has been treated with radiation therapy.
- Trial name
- NCT00931528
- Testing
- Tadalafil
- Where
- 192 sites in United States, Canada
- Volunteers
- 242 people, healthy volunteers welcome
- Sponsor
- Radiation Therapy Oncology Group
Prostatic Neoplasms
Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer
The purpose of this study is to determine the effectiveness of enzalutamide as part of adjuvant androgen deprivation therapy (ADT) with a luteinizing hormone releasing hormone analogue (LHRHA) in men having radiation therapy for…
- Trial name
- ENZARAD (NCT02446444)
- Testing
- Enzalutamide, Conventional NSAA, LHRHA
- Where
- 69 sites in United States, Australia and 7 more
- Volunteers
- 802 people
- Sponsor
- University of Sydney
Castrate Resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
This is a single-center, open-label, study of Prostate-Specific Membrane Antigen (PSMA)-targeted radionuclide therapy with 177Lu-PSMA-617 in combination with pembrolizumab in participants with metastatic castrate-resistant…
- Conditions
- Castrate Resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Carcinoma
- Trial name
- NCT05766371
- Testing
- Pembrolizumab, 177Lu-PSMA-617
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- University of California, San Francisco
Cancer, Colorectal Cancer
FOG-001 in Locally Advanced or Metastatic Solid Tumors
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).
- Conditions
- Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor
- Trial name
- NCT05919264
- Testing
- FOG-001, mFOLFOX-6, Nivolumab
- Where
- 33 sites in United States, Australia
- Volunteers
- 619 people
- Sponsor
- Parabilis Medicines, Inc.
Castration-Resistant Prostatic Cancer
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate plus prednisone (AAP) compared to AAP and placebo.
- Trial name
- MAGNITUDE (NCT03748641)
- Testing
- Niraparib, Abiraterone Acetate, Prednisone
- Where
- 318 sites in United States, Argentina and 27 more
- Volunteers
- 765 people
- Sponsor
- Janssen Research & Development, LLC
Metastatic Castration-resistant Prostate Cancer
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.
- Trial name
- NCT06067841
- Testing
- BMS-986460
- Where
- 15 sites in United States, Canada and 1 more
- Volunteers
- 140 people
- Sponsor
- Bristol-Myers Squibb
Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Hormone therapy, or androgen deprivation therapy (ADT) is a standard way to treat prostate cancer. It works by reducing the amount of the main male sex hormone, testosterone in the body.
- Conditions
- Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
- Trial name
- NCT07005154
- Testing
- ASP5541, Prednisone, Prednisolone
- Where
- 54 sites in United States, China and 10 more
- Volunteers
- 218 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Prostate Cancer
Radiolabeled Monoclonal Antibody in Treating Patients With Progressive Metastatic Androgen-Independent Adenocarcinoma (Cancer) of the Prostate
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or deliver radioactive tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00081172
- Testing
- lutetium Lu 177 monoclonal antibody J591
- Where
- 3 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Biomarker 11-dh-TXB2 in Blood and Urine Samples From Patients With Prostate Cancer and Healthy Volunteers
RATIONALE: Studying samples of blood and urine from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer.
- Trial name
- NCT00984919
- Testing
- high performance liquid chromatography, laboratory biomarker analysis, mass spectrometry
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide
This research trial studies molecular features and pathways in predicting drug resistance in patients with castration-resistant prostate cancer that has spread to other parts of the body and who are receiving enzalutamide.
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, PSA Progression
- Trial name
- NCT02228265
- Testing
- Cytology Specimen Collection Procedure, Enzalutamide, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- OHSU Knight Cancer Institute
Prostate Cancer
A Phase II Randomised Trial of Three Regimens of GX301 Vaccination in Castration-resistant Prostate Cancer
GX301 is an experimental therapeutic vaccine directed against human telomerase, an enzyme playing an essential role in cancer cell proliferation.
- Trial name
- NCT02293707
- Testing
- GX301
- Where
- 24 sites in Italy, Spain
- Volunteers
- 99 people
- Sponsor
- Laboratoires Leurquin Mediolanum
Brain and Central Nervous System Tumors, Prostate Cancer
Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer
RATIONALE: Everolimus may stop the growth of tumor cells by stopping blood flow to the tumor. Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
- Trial name
- NCT00085566
- Testing
- everolimus, gefitinib
- Where
- 2 sites in United States, Spain
- Volunteers
- 61 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Prostate Cancer
The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only
This multinational, multicenter, prospective, randomized, controlled, open label Phase 3 study is designed to investigate and confirm the benefits and risks associated with the PSMA-targeted antibody, 177Lu DOTA rosopatamab…
- Trial name
- NCT04876651
- Testing
- 177Lu-DOTA-rosopatamb, Standard of Care
- Where
- 6 sites in Australia, New Zealand
- Volunteers
- 16 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Ltd
Prostate Cancer, Cancer of Prostate
Improving Sexual Quality of Life - Randomized Trial of Two vs Five MRI Guided SABR Treatments for Prostate Cancer
Prostate Stereotactic ablative body radiotherapy (SABR) is an established technique that delivers radiation in a non-invasive approach for men with prostate cancer.
- Conditions
- Prostate Cancer, Cancer of Prostate, Prostate Adenocarcinoma
- Trial name
- iSMART (NCT05600400)
- Testing
- Stereotactic Ablative Body Radiation
- Where
- Canada
- Volunteers
- 144 people
- Sponsor
- Sunnybrook Health Sciences Centre
Androgen-independent Prostate Cancer
Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)
To determine the time to progression produced by the combination of Novantrone (mitoxantrone) and Erbitux (cetuximab) versus Novantrone alone in metastatic AIPC patients previously treated with docetaxel-based chemotherapy.
- Trial name
- NCT00661492
- Testing
- cetuximab, Mitoxantrone
- Where
- 55 sites in United States
- Volunteers
- 115 people
- Sponsor
- US Oncology Research
Prostate Cancer
Study of Metformin Plus Oligomeric Procyanidin Complex for Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients
The overall goal of this study is to identify a safe dose of metformin, in combination with oligomeric procyanidin complex (OPC) for pharmacologic reduction of AGE levels in patients with prostate cancer.
- Trial name
- NCT03465345
- Testing
- Metformin, Oligomeric Procyanidin Complex
- Where
- United States
- Sponsor
- Medical University of South Carolina
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.